Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Med Econ ; 24(1): 140-149, 2021.
Article in English | MEDLINE | ID: mdl-33461357

ABSTRACT

AIMS: Primary progressive multiple sclerosis (PPMS) has a progressive course of disability with continuous neurological worsening. We investigated societal costs of PPMS in Australia and the economic impact of increasing the independence of people with PPMS through delaying disease progression. METHODS: This prevalence-based retrospective cost-of-illness analysis used observational data from publicly available secondary data sources and literature findings. Direct and indirect costs of PPMS were considered. A replica estimated population was created using the National Centre for Social and Economic Modelling (NATSEM) microsimulation model of the Australian tax and transfer system (STINMOD+). Using a budget impact analysis approach, we modelled the effect on PPMS costs of an effective hypothetical disease-modifying treatment (DMT) that delays disease progression by a year from mild to moderate and a further year from moderate to severe PPMS. RESULTS: An estimated 31,650 Australians have multiple sclerosis (MS) including 4,430 with PPMS. The proportion with PPMS was estimated to increase with age and disease severity. Overall 25% of males with MS, and 10% of females, were estimated to have PPMS. Societal cost of PPMS in Australia in 2018 was estimated at AU$418.1 million. Indirect costs contributed 67.5% of total costs, attributable to reduced workforce participation and need for informal care. The modelled DMT was estimated to create savings of AU$14.9 million (3.6%). Fewer people had moderate and severe PPMS resulting in major cost savings, partially offset by increased costs of treatment, care and support for a relative increase in the number of people with mild PPMS and their increased productivity losses. LIMITATIONS: Publicly available data may be incomplete. The potential cost of the DMT was not considered. CONCLUSIONS: The economic burden of PPMS was estimated at AU$418 million in 2018. An effective DMT that delayed progression from disease severity states by one year could provide significant cost savings.


Subject(s)
Multiple Sclerosis, Chronic Progressive , Multiple Sclerosis , Australia , Cost of Illness , Disease Progression , Female , Health Care Costs , Humans , Male , Multiple Sclerosis, Chronic Progressive/drug therapy , Retrospective Studies
2.
Haemophilia ; 26 Suppl 5: 3-10, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32935397

ABSTRACT

INTRODUCTION: Few studies, both in Australia and overseas, have examined the social impacts of living with haemophilia A (HA) or the economic costs associated with the disorder. The purpose of this paper is to examine the epidemiology and societal burden of people with HA (PwHA) in Australia, with a particular focus on men with this disorder. METHODS: The epidemiology and societal burden of HA in Australia, with a particular focus on men with this disorder, were assessed, using data available in the Australian and international literature and publicly available data. RESULTS: The mean annual prevalence of HA is approximately 1-2 per 10 000 males. Prophylactic treatment is used in one-quarter (25.1%) of people with moderate HA, and 82.2% of people with severe HA. Within the latter group, 16.1% have inhibitors for Factor VIII, predisposing them to worse morbidity, mortality and quality of life when compared to the non-inhibitor population. Joint pain and joint disease occur commonly in PwHA, with up to 70% of adults with HA experiencing joint problems. HA is associated with poor physical health, and PwHA miss school and work due to bleeding-related events. CONCLUSION: HA is associated with substantial economic burden; with large differences in costs reported between countries. Overall, HA imposes a significant burden of disease on PwHA, their families and the community at large.


Subject(s)
Cost of Illness , Hemophilia A/epidemiology , Adolescent , Adult , Age Factors , Aged , Australia/epidemiology , Child , Child, Preschool , Factor VIII/administration & dosage , Factor VIII/adverse effects , Factor VIII/therapeutic use , Global Health/statistics & numerical data , Hemophilia A/complications , Hemophilia A/diagnosis , Hemophilia A/therapy , Hospitalization , Humans , Infant , Infant, Newborn , Male , Middle Aged , Prevalence , Public Health Surveillance , Quality of Life , Registries , Severity of Illness Index , Sex Factors , Young Adult
3.
Haemophilia ; 26 Suppl 5: 11-20, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32935398

ABSTRACT

INTRODUCTION: Although the costs for people with haemophilia A (PwHA) in Europe and the United States have been well characterized, to date, there are no cost estimates for PwHA in Australia. The purpose of this study was to estimate direct and indirect costs of moderate and severe haemophilia A (HA) in Australia under current treatment practices. METHODS: The number of Australian males with moderate or severe HA was projected from Australian Bleeding Disorders Registry (ABDR) data. We estimated the prevalence in 2018 of adults with moderate HA to be 159 people, severe to be 416; and 68 and 283, respectively, in the paediatric (aged < 18 years) population. We used a 'bottom-up prevalence based cost of illness approach' to estimate costs; that is, we estimated the per capita cost for different groups of PwHA; for example, by age and disease severity, and these per capita costs were scaled up to the estimated population with HA. Costs were estimated based on publicly available secondary data and literature review. RESULTS: The treatment-related costs, direct and indirect costs, of moderate to severe HA are significant, totalling over AUD$111M in 2018, equating to a yearly per patient cost of approximately AUD$120 000 (equivalent to ~EUR€74 000 or ~USD$85 000). CONCLUSION: Although HA affects a relatively small number of people within the Australian population, it is associated with high aggregate costs and imposes a high economic burden.


Subject(s)
Cost of Illness , Health Care Costs/statistics & numerical data , Hemophilia A/epidemiology , Australia/epidemiology , Costs and Cost Analysis , Drug Costs , Factor VIII/therapeutic use , Health Care Surveys , Hemophilia A/diagnosis , Hemophilia A/therapy , Hospitalization/economics , Hospitalization/statistics & numerical data , Humans , Male , Prevalence , Registries , Severity of Illness Index
4.
Haemophilia ; 26 Suppl 5: 21-29, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32935399

ABSTRACT

INTRODUCTION: Emicizumab is a humanized monoclonal modified IgG4 antibody with bispecific antibody structure bridging Factor IXa and Factor X. Emicizumab has demonstrated efficacy and safety in adults, adolescents and paediatrics with HA, with or without inhibitors to Factor VIII (FVIII). There is currently no evidence that reports on the potential impact of the introduction of emicizumab on the societal costs of haemophilia A (HA). The purpose of this study was to explore the cost impact associated with the introduction of emicizumab on the current societal costs of people with HA (PwHA) in Australia. METHODS: We conducted an analysis of the impact of emicizumab on societal costs, based on changes in the direct and indirect costs incurred by PwHA. Potential impacts of emicizumab on outcomes in PwHA were modelled based on HAVEN 1, HAVEN 2 and HAVEN 3 studies. We assumed that eligible PwHA commenced use of emicizumab on 1 January 2018. The impact of emicizumab on costs of HA in Australia males was then estimated for the 12-month period to 31 December 2018. RESULTS: Overall, uptake of emicizumab in its first year of use reduces annual costs associated with moderate/severe HA by AUD$69.197M (62.3%). This reflects 64.2% reduction in the cost of FVIII blood products and 92% reduction in cost of bypassing agents. CONCLUSION: The cost of emicizumab is likely to offset some or all of the projected reductions in treatment costs. However, we also found 30.7% reduction in non-treatment direct costs (AUD$3.771M) and 19.1% reduction in indirect costs (AUD$2.732M).


Subject(s)
Antibodies, Bispecific/economics , Antibodies, Monoclonal, Humanized/economics , Cost of Illness , Drug Costs , Health Care Costs , Hemophilia A/epidemiology , Adolescent , Adult , Antibodies, Bispecific/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Australia/epidemiology , Child , Child, Preschool , Costs and Cost Analysis , Drug Costs/statistics & numerical data , Factor VIII/therapeutic use , Hemophilia A/blood , Hemophilia A/drug therapy , Humans , Male , Public Health Surveillance , Treatment Outcome , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...